NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis $7.40 -0.08 (-1.07%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.27▼$7.9050-Day Range$4.76▼$7.8652-Week Range$4.59▼$20.72Volume857,791 shsAverage Volume1.31 million shsMarket Capitalization$621.30 millionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verve Therapeutics alerts: Email Address Verve Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside345.9% Upside$33.00 Price TargetShort InterestBearish23.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 6 Articles This WeekInsider TradingAcquiring Shares$475,760 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.73) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.63 out of 5 starsMedical Sector737th out of 936 stocksPharmaceutical Preparations Industry342nd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Verve Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.62% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 1.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 2.3 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Verve Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows10 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $475,760.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verve Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.73) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verve Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Verve Therapeutics Stock (NASDAQ:VERV)Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More VERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Stock News HeadlinesJuly 27 at 2:04 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 21, 2024 | ca.finance.yahoo.comVERV Aug 2024 15.000 putJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 20, 2024 | ca.finance.yahoo.comVERV Aug 2024 17.500 putJuly 9, 2024 | prnewswire.comVERV The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc.July 8, 2024 | insidermonkey.comWhy Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?July 1, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 28, 2024 | globenewswire.comVerve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of DirectorsJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."June 20, 2024 | prnewswire.comVERV Investors Have the Opportunity to Join Investigation of Verve Therapeutics, Inc. with the Schall Law FirmJune 13, 2024 | seekingalpha.comWhy Verve Therapeutics Deserves A Spot On Your WatchlistMay 31, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | globenewswire.comVerve Therapeutics Announces Leadership UpdateMay 30, 2024 | globenewswire.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 11, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong FinancialsSee More Headlines Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees255Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$55.00 Low Stock Price Target$15.00 Potential Upside/Downside+345.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,070,000.00 Net Margins-1,226.51% Pretax Margin-1,224.13% Return on Equity-37.35% Return on Assets-29.31% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$16.05 million Price / Sales38.72 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book1.01Miscellaneous Outstanding Shares83,965,000Free Float67,760,000Market Cap$621.34 million OptionableOptionable Beta1.83 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Sekar Kathiresan M.D. (Age 51)Co-Founder, CEO & Director Comp: $973.25kMs. Allison Dorval (Age 48)CFO & Principal Accounting Officer Comp: $711.76kDr. Andrew M. Bellinger M.D. (Age 46)Ph.D., Chief Scientific Officer Comp: $758.29kMr. Andrew D. Ashe J.D. (Age 57)President, COO & General Counsel Comp: $703.85kDr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Joan Nickerson M.B.A. (Age 55)Chief Administrative Officer More ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTJanux TherapeuticsNASDAQ:JANXAmneal PharmaceuticalsNASDAQ:AMRXRocket PharmaceuticalsNASDAQ:RCKTProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 3,104,413 shares on 7/26/2024Ownership: 3.497%Bank of New York Mellon CorpBought 49,922 shares on 7/26/2024Ownership: 0.327%Accredited Investors Inc.Bought 2,455 shares on 7/20/2024Ownership: 0.021%Nisa Investment Advisors LLCBought 6,949 shares on 7/20/2024Ownership: 0.009%Sumitomo Mitsui Trust Holdings Inc.Sold 1,476,732 shares on 7/19/2024Ownership: 1.329%View All Insider TransactionsView All Institutional Transactions VERV Stock Analysis - Frequently Asked Questions How have VERV shares performed this year? Verve Therapeutics' stock was trading at $13.94 at the beginning of the year. Since then, VERV shares have decreased by 46.9% and is now trading at $7.40. View the best growth stocks for 2024 here. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. The firm's revenue for the quarter was up 305.6% on a year-over-year basis. When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Top institutional shareholders of Verve Therapeutics include ARK Investment Management LLC (3.50%), Sumitomo Mitsui Trust Holdings Inc. (1.33%), Bank of New York Mellon Corp (0.33%) and Accredited Investors Inc. (0.02%). Insiders that own company stock include Krishna Yeshwant, Fmr Llc, Andrew D Ashe, Sekar Kathiresan, Burt A Adelman, Joan Nickerson, Andrew Bellinger, Allison Dorval and 2017 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERV) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VERV Stock Alerts